Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

About this update from Corvus Pharmaceuticals, Inc.

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif. , March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET ( 1:30 pm PT ) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days. About Corvus Pharmaceuticals : Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com and LinkedIn . INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals , Inc. +1-650-900-4522 [email protected] MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750 [email protected] Source: Corvus Pharmaceuticals, Inc.

View stock analysis, news, and events for Corvus Pharmaceuticals, Inc.